Novartis Financial Results 2002 - ENGLISH VIRTUAL PRESS KIT

January 23, 2003 06:00 ET | Source: Novartis Pharma AG Novartis Pharma AG

Part 1 - Media Release
http://hugin.info/134323/R/1011975/157590.pdf

Part 2 - Conference Program
http://hugin.info/134323/R/1011977/157591.pdf

Part 3 - Speakers Presentations

3.1 Daniel Vasella
http://hugin.info/134323/R/1011978/157592.pdf
http://hugin.info/134323/R/1011979/157593.pdf

3.2 Raymund Breu
http://hugin.info/134323/R/1011980/157594.pdf

3.3 Thomas Ebeling
http://hugin.info/134323/R/1011983/157595.pdf

3.4 Paul Choffat
http://hugin.info/134323/R/1011984/157596.pdf

3.5 David Epstein
http://hugin.info/134323/R/1011987/157597.pdf

Part 4 - Biographies
http://hugin.info/134323/R/1011988/157598.pdf

Part 5 - Corporate Organizational Structure
http://hugin.info/134323/R/1011989/157599.pdf

Recommended Reading

July 31, 2026 16:25 ET | Source: Novartis Pharma AG

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease

Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated results show Pluvicto reduced risk of progression or death by 33% in...
Read More
July 21, 2026 01:00 ET | Source: Novartis Pharma AG

Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed

Ad hoc announcement pursuant to Art. 53 LRSecond quarterNet sales grew +1% (cc1, +3% USD), with core operating income1 flat (cc and USD)Sales growth driven by priority brands including Kisqali (+43%...
Read More